Dicerna to Participate in Fireside Chat at the LEERINK Partners Roundtable Series
September 20 2017 - 7:30AM
Business Wire
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading
developer of investigational ribonucleic acid interference (RNAi)
therapeutics, today announced that Douglas M. Fambrough, Ph.D.,
president and chief executive officer, will participate in an
analyst-led fireside chat at the LEERINK Partners Roundtable
Series: Rare Disease and Immuno-Oncology on Wednesday, September
27, 2017 at 11:00 a.m. ET. The conference will be held at the Lotte
New York Palace in New York City.
A live webcast of the presentation can be accessed on the
Investors & Media section on the Dicerna website at
www.dicerna.com. An archived replay of the webcast will be
available on the Company’s website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company
focused on the discovery and development of innovative,
subcutaneously delivered RNAi-based therapeutics for diseases
involving the liver, including rare diseases, chronic liver
diseases, cardiovascular diseases, and viral infectious diseases.
Dicerna is leveraging its proprietary GalXC™ RNAi technology
platform to build a broad pipeline in these core therapeutic areas,
focusing on target genes where connections between target gene and
diseases are well understood and documented. Dicerna intends to
discover, develop and commercialize novel therapeutics either on
its own or in collaboration with pharmaceutical partners. For more
information, please visit www.dicerna.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170920005262/en/
Investor:Rx Communications GroupPaula Schwartz,
917-322-2216pschwartz@rxir.comorMedia:SmithSolveAlex Van
Rees, 973-442-1555 ext. 111alex.vanrees@smithsolve.com
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024